- Home
- LEGN vs PATH Comparison
LEGN vs PATH Comparison
Compare LEGN & PATH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LEGN | PATH |
|---|---|---|
| Founded | 2014 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 6.6B |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LEGN | PATH |
|---|---|---|
| Price | $17.27 | $12.08 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 13 | 17 |
| Target Price | ★ $63.08 | $14.41 |
| AVG Volume (30 Days) | 1.5M | ★ 37.5M |
| Earning Date | 03-10-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.75 |
| EPS | N/A | ★ 0.33 |
| Revenue | N/A | ★ $1,429,664,000.00 |
| Revenue This Year | $46.27 | $11.58 |
| Revenue Next Year | $28.77 | $8.57 |
| P/E Ratio | ★ N/A | $36.64 |
| Revenue Growth | N/A | ★ 9.30 |
| 52 Week Low | $16.24 | $9.38 |
| 52 Week High | $45.30 | $19.84 |
Technical Indicators
Market Signals| Indicator | LEGN | PATH |
|---|---|---|
| Relative Strength Index (RSI) | 38.56 | 52.57 |
| Support Level | $16.24 | $10.32 |
| Resistance Level | $20.39 | $13.29 |
| Average True Range (ATR) | 0.80 | 0.64 |
| MACD | -0.14 | 0.19 |
| Stochastic Oscillator | 5.42 | 70.15 |
Price Performance
Historical ComparisonAbout LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
About PATH UiPath Inc.
UiPath Inc offers an end-to-end cross-application enterprise automation platform principally with computer vision technology and user interface automations in its initial RPA offering, which remains the foundation of the platform. The platform leverages a range of automation technologies including robotic process automation, application programming interface, and artificial intelligence. UiPath's solution can automate a broad range of repetitive tasks across industries including claims processing, employee onboarding, invoice to cash, loan applications, and customer service.